Chemotherapy for metastatic melanoma : Time for a change?
β Scribed by Helen J. Gogas; John M. Kirkwood; Vernon K. Sondak
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 123 KB
- Volume
- 109
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The appearance of distant metastases in a patient with malignant melanoma usually prophesies an early death: median survival is only 5 to 8 months. Surgery definitely can palliate certain patients and lead to a prolongation of life for others. In selected surgical candidates, an isolated nonvisceral
## Abstract Melanoma has traditionally been considered an immunogenic tumor. A number of approaches have been studied for enhancement of antitumor immunity. The first cytokine approved for the treatment of metastatic melanoma, interleukinβ2, has resulted in prolonged responses in a small subset of
Change is both necessary and exciting. It holds the promise for betterment. After six years at the helm of Biotechnology & Bioengineering, I feel it is time for change, for passing on the editorship of the journal. I still enjoy very much the responsibilities and excitement of this position, but the
The summer of the giants. They weren't really giants, of course. Just nice young people who'd decided to camp outside the village for the summer. Ordinary - except they were all over six feet tall, a bit too well dressed, and didn't mix with anyone. No one thought much about them. Until the Night
## Background and objectives: Melanoma patients have a 20-27% rate of 5-year survival after surgical resection of pulmonary metastases. we evaluated tumor doubling time (tdt) and other prognostic factors in an attempt to identify candidates for pulmonary metastasectomy. ## Methods: Review of our